Accenture (ACN)

NYSEInformation TechnologyInformation Technology ServicesSnapshot 2026-10-15

$229.68+2.12%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Accenture’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+1.3%

+10% or more+5%0%−5%−10% or less

15.75 → 15.96 EPS · FY ending Aug 31, 2028 · 16 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 12 to 16; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

4 key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain capital return via share buybacks	A supporting condition in Accenture's published investment case. The stated target is Buyback program of $7.5B in FY26.	Intact	Buyback program is reduced or suspended in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 5 of last 5 quarters. Free cash flow increased from $10.87 billion in fiscal 2025 to $11.62 billion in fiscal 2026, within the targeted range of $10.8 billion to $11.5 billion. Management has consistently maintained this priority and is delivering on it. Delivery assessment Oct 15, 2026
Generate free cash flow of $10.8B to $11.5B	Free cash flow is solid, targeting $10.8B to $11.5B in fiscal 2026.	Intact	Free cash flow falls below $10.8B in FY26	Free cash flow: $2.845B FY2026-Q4; GAAP. Published target: $10.8B to $11.5B. Target period is not explicitly aligned with this observation. Source published Oct 1, 20262,845,142,000 USD · calculatedSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Aug 31, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 5 of last 5 quarters. Free cash flow increased from $10.87 billion in fiscal 2025 to $11.62 billion in fiscal 2026, within the targeted range of $10.8 billion to $11.5 billion. Management has consistently maintained this priority and is delivering on it. Delivery assessment Oct 15, 2026
Maintain operating margin near 15.6%	Profit margins stay strong near 15.6%.	Improving	Operating margin falls below 14% in FY26	Operating margin: 15.33% FY2026-Q4; GAAP. Published target: ~15.6%. Target period is not explicitly aligned with this observation. Source published Oct 1, 202615.329515 percent · calculatedSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Aug 31, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve full-year revenue growth of 3% to 5% in local currency	A primary condition in Accenture's published investment case. The stated target is 3% to 5% YoY growth.	Intact	YoY revenue growth falls below 3% in FY26	Revenue growth: 6.15% FY2026-Q4; GAAP. Published target: 3% to 5% YoY growth. Target period is not explicitly aligned with this observation. Source published Oct 1, 20266.153865 percent · calculatedSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Aug 31, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 5 of last 5 quarters. Fiscal 2026 revenues grew from $69.7 billion in 2025 to $74.2 billion in 2026, a 5% increase in local currency, consistent with management's guidance of 3% to 6% growth. The trajectory matches management's stated growth expectations. Delivery assessment Oct 15, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-08-31 · fmp

FY2028 EPS$15.96

$15.74 → $15.96 · observed estimates

FY2028 revenue$81.35B

$80.64B → $81.35B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-09-01	$15.74	$80,640,325,219	12 / 21
2026-09-02	$15.74	$80,640,325,219	12 / 21
2026-09-03	$15.74	$80,640,325,219	12 / 21
2026-09-04	$15.74	$80,640,325,219	12 / 21
2026-09-05	$15.74	$80,640,325,219	12 / 21
2026-09-06	$15.74	$80,640,325,219	12 / 21
2026-09-07	$15.74	$80,640,325,219	12 / 21
2026-09-08	$15.74	$80,640,325,219	12 / 21
2026-09-09	$15.74	$80,640,325,219	12 / 21
2026-09-10	$15.74	$80,640,325,219	12 / 21
2026-09-11	$15.74	$80,640,325,219	12 / 21
2026-09-12	$15.73	$80,599,623,892	12 / 21
2026-09-13	$15.75	$80,519,093,944	12 / 21
2026-09-14	$15.75	$80,519,093,944	12 / 21
2026-09-15	$15.75	$80,518,862,366	12 / 21
2026-09-16	$15.74	$80,436,205,474	12 / 21
2026-09-17	$15.74	$80,436,205,474	12 / 21
2026-09-18	$15.74	$80,436,205,474	12 / 21
2026-09-19	$15.74	$80,436,205,474	12 / 21
2026-09-20	$15.74	$80,380,557,693	11 / 20
2026-09-21	$15.74	$80,380,557,693	12 / 21
2026-09-22	$15.74	$80,380,557,693	12 / 21
2026-09-23	$15.67	$80,158,366,453	12 / 21
2026-09-24	$15.67	$80,158,366,453	12 / 21
2026-09-25	$15.65	$80,059,189,272	12 / 22
2026-09-26	$15.63	$80,039,873,482	12 / 22
2026-09-27	$15.63	$80,039,873,482	12 / 22
2026-09-28	$15.63	$80,039,873,482	12 / 22
2026-09-29	$15.63	$80,039,873,482	12 / 22
2026-09-30	$15.63	$80,039,873,482	12 / 22
2026-10-01	$15.63	$79,961,731,010	12 / 22
2026-10-02	$15.92	$81,250,264,339	19 / 24
2026-10-03	$15.97	$81,310,606,122	15 / 18
2026-10-04	$15.97	$81,310,606,122	15 / 18
2026-10-05	$15.97	$81,310,606,122	15 / 18
2026-10-06	$15.97	$81,351,474,558	15 / 18
2026-10-07	$15.99	$81,351,474,558	15 / 18
2026-10-08	$15.96	$81,351,474,558	15 / 18
2026-10-09	$15.96	$81,351,476,023	15 / 18
2026-10-10	$15.96	$81,351,476,023	15 / 18
2026-10-11	$15.96	$81,351,476,023	15 / 18
2026-10-12	$15.96	$81,351,476,023	15 / 18
2026-10-13	$15.96	$81,351,476,023	16 / 19
2026-10-14	$15.96	$81,351,476,023	16 / 19
2026-10-15	$15.96	$81,351,476,023	16 / 18

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	19	10
2026-06-01	18	13
2026-07-01	15	13
2026-08-01	14	13
2026-09-01	14	15
2026-10-01	12	16

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 12 Buy / Strong Buy · 16 Hold · 0 Sell / Strong Sell

0 upgrades1 downgrades15 maintains

Recent actions · Sep 16–Oct 15 · 16 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSOct 15 · prior Jul 8

$275.00 → $278.00+1.1%

SusquehannaOct 15 · prior Oct 1

$210.00 → $230.00+9.5%

Stifel NicolausOct 15 · prior Jun 3

$270.00 → $242.00-10.4%

Mizuho SecuritiesOct 6 · prior Jun 23

$226.00 → $241.00+6.6%

Wells FargoOct 2 · prior Jul 20

$194.00 → $210.00+8.2%

Truist FinancialOct 2 · prior Jun 22

$150.00 → $220.00+46.7%

RBC CapitalOct 2 · prior Sep 15

$195.00 → $240.00+23.1%

Morgan StanleyOct 2 · prior Sep 14

$175.00 → $195.00+11.4%

JefferiesOct 2

$220.00New observation · no comparable prior

BMO CapitalOct 2 · prior Sep 23

$200.00 → $235.00+17.5%

Argus ResearchOct 2

$260.00New observation · no comparable prior

Robert W. BairdOct 1 · prior Jun 18

$190.00 → $245.00+28.9%

Goldman SachsOct 1 · prior Jun 3

$270.00 → $260.00-3.7%

Evercore ISIOct 1 · prior Jun 18

$180.00 → $250.00+38.9%

Deutsche BankSep 18 · prior Jul 10

$136.00 → $175.00+28.7%

$0$152.90$305.80

11 raises · 2 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain capital return via share buybacksDirect metric needs a verified mapping
Generate free cash flow of $10.8B to $11.5BFree cash flow: $2.845B
Maintain operating margin near 15.6%Operating margin: 15.33%
Achieve full-year revenue growth of 3% to 5% in local currencyRevenue growth: 6.15%

Next proof point

Next earnings date unavailable

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-56.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Accenture outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment is characterized as a durable compounder, given its consistent revenue and earnings growth. The current thesis state is intact, supported by strong recent financial performance and a commitment to returning cash to shareholders.

What's priced into Accenture

The market appears to have priced in a low level of execution fragility, with expectations slightly below actual performance. Valuation is considered cheap compared to peers, suggesting that the stock may be undervalued relative to its fundamentals.

What the fundamentals likely do

Fundamentals are likely to remain stable, as management is on track to meet its growth and earnings targets. However, there is a high risk associated with potential guidance cuts, which could negatively impact sentiment.

What Accenture hinges on

The thesis hinges on several factors, including the Federal Reserve's interest rate decisions and the performance of sector peers like IBM and CTSH. Positive momentum from these companies could support ACN's growth trajectory.